References
- Minota S. Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company. Mod Rheumatol. 2014;Jun 2:1–2, [Epub ahead of print] (doi:10.3109/14397595.2014.917600).
- Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich S, and the Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011;63(8):1150–8.
- van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–70.
- Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum. 2012;64(4):970–81.